Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bismuth-213 IgG monoclonal antibody conjugates - Radimmune Therapeutics

Next Previous
Search
Drug Profile

Research programme: bismuth-213 IgG monoclonal antibody conjugates - Radimmune Therapeutics

Alternative Names: 213Bi-IgG mAb conjugates - RadImmune Therapeutics; 213Bi-IgG 8C3 monoclonal antibody conjugate - RadImmune Therapeutics; Bismuth-213 IgG 8C3 monoclonal antibody conjugate - RadImmune Therapeutics

Latest Information Update: 04 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Albert Einstein College of Medicine; RadImmune Therapeutics; University of Saskatchewan
  • Class Immunoconjugates; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
  • 14 Nov 2018 RadImmune Therapeutics collaborates with Goodwin Biotechnology and University of Saskatchewan for development of a manufacturing process for it lead bismuth-213 IgG monoclonal antibody conjugate
  • 14 Nov 2018 RadImmune Therapeutics plans a phase I trial for 213Bi labelled IgG mAb conjugate for Malignant melanoma in 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top